48,830
edits
Difference between revisions of "Immunohistochemical staining"
Jump to navigation
Jump to search
Immunohistochemical staining (view source)
Revision as of 19:06, 27 September 2011
, 19:06, 27 September 2011wikify
(wikify) |
|||
| Line 14: | Line 14: | ||
{{familytree | | | | | | | | | | | A | | | | | | | | | | |A=Malignancy}} | {{familytree | | | | | | | | | | | A | | | | | | | | | | |A=Malignancy}} | ||
{{familytree | |,|-|-|-|v|-|-|-|v|-|^|-|v|-|-|-|v|-|-|-|.| |}} | {{familytree | |,|-|-|-|v|-|-|-|v|-|^|-|v|-|-|-|v|-|-|-|.| |}} | ||
{{familytree | B | | C | | D | | E | | F | |G |B=Epithelial<br>(Carcinoma)|C=Mesenchymal<br>(Sarcoma)|D=Germ cell<br>tumour|E=Neuroendocrine<br>carcinoma|F=Hematologic|G=Malignant<br>melanoma}} | {{familytree | B | | C | | D | | E | | F | |G |B=Epithelial<br>(Carcinoma)|C=Mesenchymal<br>(Sarcoma)|D=Germ cell<br>tumour|E=[[Neuroendocrine tumours|Neuroendocrine<br>carcinoma]]|F=Hematologic|G=[[Melanoma|Malignant<br>melanoma]]}} | ||
{{familytree/end}} | {{familytree/end}} | ||
| Line 89: | Line 89: | ||
*D2-40 +ve in ChRCC. | *D2-40 +ve in ChRCC. | ||
Xanthogranulomatous pyelonephritis: | [[Xanthogranulomatous pyelonephritis]]: | ||
*CD68 (for macrophages). | *CD68 (for macrophages). | ||
| Line 118: | Line 118: | ||
*TTF-1. | *TTF-1. | ||
===Pancreas=== | ===[[Pancreas]]=== | ||
*CK17 - approx. 50% of [[pancreas|pancreatico]]biliary adenocarcinomas & patchy.<ref name=pmid11345833>{{cite journal |author=Goldstein NS, Bassi D |title=Cytokeratins 7, 17, and 20 reactivity in pancreatic and ampulla of vater adenocarcinomas. Percentage of positivity and distribution is affected by the cut-point threshold |journal=Am. J. Clin. Pathol. |volume=115 |issue=5 |pages=695–702 |year=2001 |month=May |pmid=11345833 |doi=10.1309/1NCM-46QX-3B5T-7XHR |url=}}</ref> | *CK17 - approx. 50% of [[pancreas|pancreatico]]biliary adenocarcinomas & patchy.<ref name=pmid11345833>{{cite journal |author=Goldstein NS, Bassi D |title=Cytokeratins 7, 17, and 20 reactivity in pancreatic and ampulla of vater adenocarcinomas. Percentage of positivity and distribution is affected by the cut-point threshold |journal=Am. J. Clin. Pathol. |volume=115 |issue=5 |pages=695–702 |year=2001 |month=May |pmid=11345833 |doi=10.1309/1NCM-46QX-3B5T-7XHR |url=}}</ref> | ||
*CK19.<ref name=pmid18318589>{{cite journal |author=Geller SA, Dhall D, Alsabeh R |title=Application of immunohistochemistry to liver and gastrointestinal neoplasms: liver, stomach, colon, and pancreas |journal=Arch. Pathol. Lab. Med. |volume=132 |issue=3 |pages=490–9 |year=2008 |month=March |pmid=18318589 |doi= |url=}}</ref> | *CK19.<ref name=pmid18318589>{{cite journal |author=Geller SA, Dhall D, Alsabeh R |title=Application of immunohistochemistry to liver and gastrointestinal neoplasms: liver, stomach, colon, and pancreas |journal=Arch. Pathol. Lab. Med. |volume=132 |issue=3 |pages=490–9 |year=2008 |month=March |pmid=18318589 |doi= |url=}}</ref> | ||
| Line 189: | Line 189: | ||
===Specific entities=== | ===Specific entities=== | ||
====Follicular lymphoma==== | ====[[Follicular lymphoma]]==== | ||
*CD10 +ve, BCL6 +ve. | *CD10 +ve, BCL6 +ve. | ||
| Line 195: | Line 195: | ||
*CD5 +ve, CD23 +ve. | *CD5 +ve, CD23 +ve. | ||
====Mantle cell lymphoma==== | ====[[Mantle cell lymphoma]]==== | ||
*Cyclin D1 +ve. | *Cyclin D1 +ve. | ||
**[[AKA]] Bcl-1.<ref>URL: [http://atlasgeneticsoncology.org/Genes/BCL1.html http://atlasgeneticsoncology.org/Genes/BCL1.html]. Accessed on: 17 December 2010.</ref> | **[[AKA]] Bcl-1.<ref>URL: [http://atlasgeneticsoncology.org/Genes/BCL1.html http://atlasgeneticsoncology.org/Genes/BCL1.html]. Accessed on: 17 December 2010.</ref> | ||
| Line 208: | Line 208: | ||
==Germ cell tumours== | ==Germ cell tumours== | ||
{{Main|Germ cell tumours}} | {{Main|Germ cell tumours}} | ||
===Seminoma=== | ===[[Seminoma]]=== | ||
*D2-40 +ve.<ref name=pmid18045648/> | *D2-40 +ve.<ref name=pmid18045648/> | ||
*OCT 3/4 +ve. | *OCT 3/4 +ve. | ||
===Embryonal carcinoma=== | ===[[Embryonal carcinoma]]=== | ||
*CD30 +ve - cytoplasm, cell membrane, Golgi. | *CD30 +ve - cytoplasm, cell membrane, Golgi. | ||
**Rarely positive in seminoma. | **Rarely positive in seminoma. | ||
| Line 218: | Line 218: | ||
*AE1/AE3 +ve. | *AE1/AE3 +ve. | ||
===Yolk sac tumour (endodermal sinus tumour)=== | ===[[Yolk sac tumour]] (endodermal sinus tumour)=== | ||
*AFP (alpha fetoprotein). | *AFP (alpha fetoprotein). | ||
===Choriocarcinoma=== | ===[[Choriocarcinoma]]=== | ||
*beta-hCG. | *beta-hCG. | ||
| Line 231: | Line 231: | ||
*D2-40 = seminoma. | *D2-40 = seminoma. | ||
==Spindle cell lesions | ==Spindle cell lesions== | ||
{{Main|Spindle cell lesions}} | {{Main|Spindle cell lesions}} | ||
Abbreviated spindle cell panel (memory device ''SCADS''): | Abbreviated spindle cell panel (memory device ''SCADS''): | ||
| Line 271: | Line 271: | ||
*[[endometrium|Endometrial]]. | *[[endometrium|Endometrial]]. | ||
*[[lung tumours|Lung]] (adenocarcinoma). | *[[lung tumours|Lung]] (adenocarcinoma). | ||
* | *[[Mesothelioma]]. | ||
*[[Salivary gland]]. | *[[Salivary gland]]. | ||
*[[Thyroid gland]] (all). | *[[Thyroid gland]] (all). | ||
| Line 284: | Line 284: | ||
*[[Ovary]], mucinous subtype. | *[[Ovary]], mucinous subtype. | ||
*Occasionally gastric adenocarcinoma, cholangiocarcinoma. | *Occasionally gastric adenocarcinoma, cholangiocarcinoma. | ||
*Transitional cell carcinoma | *"Transitional cell carcinoma" (urothelial cell carcinoma).§ | ||
*Esophagus (adenocarcinoma). | *Esophagus (adenocarcinoma). | ||
Mnemonic: ''POOTE''. | Mnemonic: ''POOTE''. | ||
Note: | Note: | ||
*[[Transitional cell carcinoma of the ovary]] is usu. CK20 -ve.<ref name=pmid21073751>{{Cite journal | last1 = Tazi | first1 = EM. | last2 = Lalya | first2 = I. | last3 = Tazi | first3 = MF. | last4 = Ahellal | first4 = Y. | last5 = M'rabti | first5 = H. | last6 = Errihani | first6 = H. | title = Transitional cell carcinoma of the ovary: a rare case and review of literature. | journal = World J Surg Oncol | volume = 8 | issue = | pages = 98 | month = | year = 2010 | doi = 10.1186/1477-7819-8-98 | PMID = 21073751 }}</ref> | *§ - [[Transitional cell carcinoma of the ovary]] is usu. CK20 -ve.<ref name=pmid21073751>{{Cite journal | last1 = Tazi | first1 = EM. | last2 = Lalya | first2 = I. | last3 = Tazi | first3 = MF. | last4 = Ahellal | first4 = Y. | last5 = M'rabti | first5 = H. | last6 = Errihani | first6 = H. | title = Transitional cell carcinoma of the ovary: a rare case and review of literature. | journal = World J Surg Oncol | volume = 8 | issue = | pages = 98 | month = | year = 2010 | doi = 10.1186/1477-7819-8-98 | PMID = 21073751 }}</ref> | ||
====CK7- CK20-==== | ====CK7- CK20-==== | ||
*Neuroendocrine lung (small cell carcinoma). | *Neuroendocrine lung (small cell carcinoma). | ||
*Adrenocortical carcinoma (ACC). | *[[Adrenocortical carcinoma]] (ACC). | ||
*Squamous cell carcinoma (all sites of the body). | *[[Squamous cell carcinoma]] (all sites of the body). | ||
*Hepatocellular carcinoma (HCC). | *[[Hepatocellular carcinoma]] (HCC). | ||
*[[Thymoma]]. | *[[Thymoma]]. | ||
*Urogenital tumours - [[germ cell tumour]]s. | *Urogenital tumours - [[germ cell tumour]]s. | ||